The profile of naturally occurring antibodies to amyloid-β (NAbs-Aβ) is altered in patients with Alzheimer’s disease (AD). However, the diagnostic potential of NAbs-Aβ for AD is not clear yet.
Objective:
This study aims to investigate the diagnostic capacities of NAbs-Aβ for AD.
Methods:
A total of 40 AD patients and 40 cognitively normal (CN) controls were enrolled in this study. Levels of NAbs-Aβ were detected by ELISA. The correlations of NAbs-Aβ levels with cognitive function and AD-associated biomarkers were examined by Spearman correlation analysis. Diagnostic abilities of NAbs-Aβ were evaluated by the receiver operating characteristic (ROC) curve analyses. The integrative diagnostic models were established by logistic regression models.
Results:
We found that NAbs-Aβ7-18 had the highest diagnostic capability (AUC = 0.72) among all single NAbs-Aβ. The combined model (NAbs-Aβ7-18, NAbs-Aβ19-30, and NAbs-Aβ25-36) had a noticeable improvement (AUC = 0.84) in the diagnostic capacity compared with each single NAbs-Aβ.
Conclusion:
NAbs-Aβs are promising in the diagnosis of AD. Further investigations are needed to confirm the translational potential of this diagnostic strategy.
WuYT, BeiserAS, BretelerMMB, FratiglioniL, HelmerC, HendrieHC, HondaH, IkramMA, LangaKM, LoboA, MatthewsFE, OharaT, PérèsK, QiuC, SeshadriS, SjölundBM, SkoogI, BrayneC (2017) The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol13, 327–339.
2.
PrinceM, BryceR, AlbaneseE, WimoA, RibeiroW, FerriCP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement9, 63–75.e62.
3.
(2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol18, 88–106.
4.
CummingsJ, LeeG, RitterA, SabbaghM, ZhongK (2020) Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y)6, e12050.
5.
RosenbergRN (2015) Defining amyloid pathology in persons with and without dementia syndromes: Making the right diagnosis. JAMA313, 1913–1914.
6.
MolinuevoJL, AytonS, BatrlaR, BednarMM, BittnerT, CummingsJ, FaganAM, HampelH, MielkeMM, MikulskisA, O’BryantS, ScheltensP, SevignyJ, ShawLM, SoaresHD, TongG, TrojanowskiJQ, ZetterbergH, BlennowK (2018) Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol136, 821–853.
7.
BraakH, Del TrediciK (2015) Neuroanatomy and pathology of sporadic Alzheimer’s disease. Adv Anat Embryol Cell Biol215, 1–162.
8.
BachJP, DodelR (2012) Naturally occurring autoantibodies against β-amyloid. Adv Exp Med Biol750, 91–99.
9.
BritschgiM, OlinCE, JohnsHT, Takeda-UchimuraY, LeMieuxMC, RufibachK, RajadasJ, ZhangH, TomookaB, RobinsonWH, ClarkCM, FaganAM, GalaskoDR, HoltzmanDM, JutelM, KayeJA, LemereCA, LeszekJ, LiG, PeskindER, QuinnJF, YesavageJA, GhisoJA, Wyss-CorayT (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci U S A106, 12145–12150.
10.
MoirRD, TseitlinKA, SosciaS, HymanBT, IrizarryMC, TanziRE (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer’s disease patients. J Biol Chem280, 17458–17463.
11.
GrudenMA, DavidovaTB, MalisauskasM, SewellRD, VoskresenskayaNI, WilhelmK, ElistratovaEI, SherstnevVV, Morozova-RocheLA (2007) Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: Autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol186, 181–192.
12.
LiuYH, WangJ, LiQX, FowlerCJ, ZengF, DengJ, XuZQ, ZhouHD, DoeckeJD, VillemagneVL, LimYY, MastersCL, WangYJ (2021) Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease. Sci Adv7, eabb0457.
13.
WangYR, WangMT, ZengXQ, LiuYH, WangYJ (2022) Associations of naturally occurring antibodies to presenilin-1 with brain amyloid-β load and cognitive impairment in Alzheimer’s disease. J Alzheimers Dis90, 1493–1500.
VandersticheleH, BiblM, EngelborghsS, Le BastardN, LewczukP, MolinuevoJL, ParnettiL, Perret-LiaudetA, ShawLM, TeunissenC, WoutersD, BlennowK (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement8, 65–73.
16.
O’BryantSE, GuptaV, HenriksenK, EdwardsM, JerominA, ListaS, BazenetC, SoaresH, LovestoneS, HampelH, MontineT, BlennowK, ForoudT, CarrilloM, Graff-RadfordN, LaskeC, BretelerM, ShawL, TrojanowskiJQ, SchupfN, RissmanRA, FaganAM, OberoiP, UmekR, WeinerMW, GrammasP, PosnerH, MartinsR (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement11, 549–560.
17.
JackCRJr., KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol12, 207–216.
18.
HonigLS, VellasB, WoodwardM, BoadaM, BullockR, BorrieM, HagerK, AndreasenN, ScarpiniE, Liu-SeifertH, CaseM, DeanRA, HakeA, SundellK, Poole HoffmannV, CarlsonC, KhannaR, MintunM, DeMattosR, SelzlerKJ, SiemersE (2018) Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med378, 321–330.
19.
SallowayS, SperlingR, FoxNC, BlennowK, KlunkW, RaskindM, SabbaghM, HonigLS, PorsteinssonAP, FerrisS, ReichertM, KetterN, NejadnikB, GuenzlerV, MiloslavskyM, WangD, LuY, LullJ, TudorIC, LiuE, GrundmanM, YuenE, BlackR, BrashearHR, Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med370, 322–333.
20.
SchindlerSE, SutphenCL, TeunissenC, McCueLM, MorrisJC, HoltzmanDM, MulderSD, ScheltensP, XiongC, FaganAM (2018) Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years. Alzheimers Dement14, 62–70.
21.
ThijssenEH, La JoieR, WolfA, StromA, WangP, IaccarinoL, BourakovaV, CobigoY, HeuerH, SpinaS, VandeVredeL, ChaiX, ProctorNK, AireyDC, ShcherbininS, Duggan EvansC, SimsJR, ZetterbergH, BlennowK, KarydasAM, TeunissenCE, KramerJH, GrinbergLT, SeeleyWW, RosenH, BoeveBF, MillerBL, RabinoviciGD, DageJL, RojasJC, BoxerAL (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med26, 387–397.
22.
PalmqvistS, JanelidzeS, QuirozYT, ZetterbergH, LoperaF, StomrudE, SuY, ChenY, SerranoGE, LeuzyA, Mattsson-CarlgrenN, StrandbergO, SmithR, VillegasA, Sepulveda-FallaD, ChaiX, ProctorNK, BeachTG, BlennowK, DageJL, ReimanEM, HanssonO (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA324, 772–781.
OstrowitzkiS, LasserRA, DorflingerE, ScheltensP, BarkhofF, NikolchevaT, AshfordE, RetoutS, HofmannC, DelmarP, KleinG, AndjelkovicM, DuboisB, BoadaM, BlennowK, SantarelliL, FontouraP, Investigators SCR (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther9, 95.
25.
RinneJO, BrooksDJ, RossorMN, FoxNC, BullockR, KlunkWE, MathisCA, BlennowK, BarakosJ, OkelloAA, Rodriguez Martinez de LianoS, LiuE, KollerM, GreggKM, SchenkD, BlackR, GrundmanM (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol9, 363–372.
26.
DoodyRS, ThomasRG, FarlowM, IwatsuboT, VellasB, JoffeS, KieburtzK, RamanR, SunX, AisenPS, SiemersE, Liu-SeifertH, MohsR, Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med370, 311–321.
27.
YangT, DangY, OstaszewskiB, MengelD, SteffenV, RabeC, BittnerT, WalshDM, SelkoeDJ (2019) Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid. Ann Neurol86, 215–224.
28.
WangT, XieXX, JiM, WangSW, ZhaJ, ZhouWW, YuXL, WeiC, MaS, XiZY, PangGL, LiuRT (2016) Naturally occurring autoantibodies against Abeta oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer’s disease than intravenous immunoglobulin. Neuropharmacology105, 561–576.
29.
AytonS, JanelidzeS, RobertsB, PalmqvistS, KalinowskiP, DioufI, BelaidiAA, StomrudE, BushAI, HanssonO (2021) Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ɛ4, sex and age. Prog Neurobiol198, 101904.
30.
FaniL, AhmadS, IkramMK, GhanbariM, IkramMA (2021) Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study. Alzheimers Dement17, 446–456.
31.
JohnA, ReddyPH (2021) Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev65, 101208.
32.
BuXL, SunPY, FanDY, WangJ, SunHL, ChengY, ZengGH, ChenDW, LiHY, YiX, ShenYY, MilesLA, MaruffP, GuBJ, FowlerCJ, MastersCL, WangYJ (2022) Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease. Sci Adv8, eabm5667.
33.
JianJM, FanDY, TianDY, ChengY, SunPY, TanCR, ZengGH, HeCY, WangYR, ZhuJ, YaoXQ, WangYJ, LiuYH (2022) Naturally-occurring antibodies against bim are decreased in Alzheimer’s disease and attenuate AD-type pathology in a mouse model. Neurosci Bull38, 1025–1040.
34.
JianJM, FanDY, ChengY, ShenYY, ChenDW, LiHY, ChenY, ZhangY, ZengGH, TanCR, LiuYH, WangYJ (2022) Circulating naturally occurring antibodies to P2RY2 are decreased in Alzheimer’s disease. J Alzheimers Dis87, 711–719.
